

Consolidated Financial Results for the First Quarter of FY2018

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2017 Q1		FY2018 Q1		YoY
	Apr. 2017-Jun. 2017		Apr. 2018-Jun. 2018		
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	12,813	100.0 %	12,761	100.0 %	99.6%
Cost of Sales	7,751	60.5%	7,449	58.4%	96.1%
Gross Profit	5,062	39.5%	5,311	41.6%	104.9%
Selling, General and Administrative Expenses	3,986	31.1%	4,086	32.0%	102.5%
Operating Income	1,077	8.4%	1,217	9.5%	113.0%
Profit Attributable to Owners of Parent	1,043	8.1%	1,062	8.3%	101.8%

Forecast of Consolidated Financial Results for the FY2018

	FY2017 Actual		FY2018 Forecast	
	Apr. 2017-Mar. 2018		Apr. 2018-Mar. 2019	
	Millions of Yen	Ratio	Millions of Yen	Ratio
Net Sales	48,994	100.0%	49,000	100.0%
Operating Income	2,824	5.8%	1,000	2.0%
Profit Attributable to Owners of Parent	2,388	4.9%	1,000	2.0%

Sales of Main Products

(Billions of yen)

Therapeutic Category	Products	FY2017 Q1 Actual	FY2018 Q1 Actual	FY2018 Forecast
Antihypertensive agent	CANDESARTAN*	3.56	3.17	11.73
Thyroid hormone	THYRADIN	1.31	1.98	5.52
Hyperlipidemic agent	LIPDIL	1.16	0.80	3.38
LH-RH derivative	LEUPRORELIN	0.99	1.01	4.54
Prostate cancer therapeutic agent	BICALUTAMIDE	0.45	0.32	1.17
Antihypertensive agent	AMLODIPINE	0.44	0.36	1.37
Emergency contraceptive	NORLEVO	0.32	0.31	1.26
Antithyroid agent	MERCAZOLE	0.28	0.31	1.15
Poorly absorbable antimicrobial agent	RIFXIMA	0.15	0.54	2.94

*Including CANDESARTAN formulation's sales